Constantin Meyer - STADA Arzneimittel Insider

STDAF -- USA Stock  

USD 96.10  0.00  0.00%

  Executive
Mr. Constantin Meyer was Member of the Supervisory Board of STADA Arzneimittel AG from 2003 to August 26 2016. Since 1974 He was Chairman of the Examination Board for Pharmaceutical Technicians and Assistants of the Lower Saxon Chamber of Pharmacists. He has previously worked as a control manager and pharmaceutical advisor. From 1986 to 1992 he was responsible for the growth of MEDICA MEYER until its merger with Phabil Bielefeld. In 1986 he became Chairman of the Advisory Board of STADA Arzneimittel AG. He studied pharmacy at LudwigsUniversitaet zu Freiburg in Breisgau Germany and gained his pharmaceutical licence in 1971.
Age: 72  Executive Since 2003      
49 6101 603 0  http://www.stada.de

Management Efficiency

The company has return on total asset (ROA) of 6.33 % which means that it generated profit of $6.33 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 14.86 % meaning that it generated $14.86 on every $100 dollars invested by stockholders.
The company has accumulated 1.65 B in total debt with debt to equity ratio (D/E) of 123.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. STADA Arzneimittel Aktiengesellschaft has Current Ratio of 1.22 suggesting that it may have difficulties to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Shigeru DosekiMitsubishi Tanabe Pharma Corpor
2017
Gabriele EismannMerck Kommanditgesellschaft auf
2014
Veit UlshoeferMerck Kommanditgesellschaft auf
2016
Michaela GlenckMerck Kommanditgesellschaft auf
N/A
Saunak SavlaDr Reddys Laboratories Limited
2016
Edeltraud GlaenzerMerck Kommanditgesellschaft auf
N/A
Michael FletterichMerck Kommanditgesellschaft auf
2014
Mikio HimizuMitsubishi Tanabe Pharma Corpor
2017
Peter SpeirsHikma Pharmaceuticals PLC
2012
Bill MacdonaldAurora Cannabis
N/A
Minoru MuramatsuMitsubishi Tanabe Pharma Corpor
N/A
Riaan VersterAspen Pharmacare Holdings Limit
2013
Allan CleirenAurora Cannabis
2017
Constantin BirnstielMerck Kommanditgesellschaft auf
2017
Bryan HotstonHikma Pharmaceuticals PLC
N/A
Neil BelotAurora Cannabis
2017
Tobias ThelenMerck Kommanditgesellschaft auf
2014
Kazuyuki HirakosoMitsubishi Tanabe Pharma Corpor
2015
Crocifissa AttardoMerck Kommanditgesellschaft auf
2009
Matsuo KikuchiMitsubishi Tanabe Pharma Corpor
N/A
Mechthild AugeMerck Kommanditgesellschaft auf
2009

Entity Summary

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH. STADA Arzneimittel operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 10232 people.STADA Arzneimittel Aktiengesellschaft (STDAF) is traded on OTC Market in USA. It is located in Stadastrasse 2-18 and employs 10,232 people.

STADA Arzneimittel Leadership Team

Carl Oetker, Member of the Supervisory Board
JanNicolas Garbe, Member of the Supervisory Board
Dieter Koch, Member of the Supervisory Board
Eckhard Brueggemann, Member of the Supervisory Board
Mark Keatley, CFO, Member of the Executive Board
Ralph Grobecker, Managing Director of OTC segment
Martin Abend, Chairman of the Supervisory Board
Matthias Wiedenfels, Chief Bus. Devel. and Central Services Officer and Member of Executive Board
Arnold Hertzsch, Member of the Supervisory Board
Halil Duru, Member of the Supervisory Board
Tina Mueller, Member of the Supervisory Board
Engelbert Willink, Chairman of the Executive Board, CEO
Barthold Piening, Chief Technical Operations Officer, Member of the Executive Board
Steffen Wagner, Member of the Management Board, Head of Europe
Helmut Kraft, CFO and Member of Executive Board
Ute Pantke, Member of the Supervisory Board
Carsten Cron, Member of the Management Board, Head Emerging Markets
Frank Seiler, IR Contact Officer
Hartmut Retzlaff, Chairman of The Executive Board
Bernhard Duettmann, CFO
Miguel Pagan, Member of the Executive Board
Claudio Albrecht, Chairman of the Executive Board, CEO
Michael Siefke, Member of the Supervisory Board
Leslie Iltgen, Vice President Investor Relations
Eric Cornut, Member of the Supervisory Board
Peter Goldschmidt, Chairman of the Executive Board
Robert Knerr, Member of the Management Board, Head of Business Development
Jens Steegers, Member of the Supervisory Board
Birgit Kudlek, Member of the Supervisory Board
Guenter Au, Chairman of the Supervisory Board
Constantin Meyer, Member of the Supervisory Board
Rolf Hoffmann, Member of the Supervisory Board
Markus Metzger, Director of Investor Relations
Benjamin Kunstler, Member of the Supervisory Board
Gunnar Riemann, Member of the Supervisory Board
Bruno Schick, Member of the Supervisory Board

Stock Performance Indicators

Current Sentiment - STDAF

STADA Arzneimittel Investor Sentiment

Macroaxis portfolio users are evenly split in their outlook on investing in STADA Arzneimittel Aktiengesellschaft. What is your outlook on investing in STADA Arzneimittel Aktiengesellschaft? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip
Currently Active Assets on Macroaxis
CRM   
Purchased a lot of shares of
few days ago
Traded for 156.0
CRM   
Purchased a lot of shares of
few days ago
Traded for 156.0
F   
Purchased over 300 shares of
few days ago
Traded for 9.81
C   
Purchased over 40 shares of
few days ago
Traded for 74.735
GM   
Purchased over 70 shares of
few days ago
Traded for 36.08
Also please take a look at World Market Map. Please also try Portfolio Manager module to state of the art portfolio manager to monitor and improve performance of your invested capital.
Search macroaxis.com